Pfizer Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $62.58B | $63.63B | $58.50B | $100.33B | $81.29B | $41.91B | $40.91B |
| US | — | — | — | $27.08B | $42.31B | $29.74B | $21.85B | — |
| International | — | — | — | $31.42B | $58.02B | $51.55B | $20.06B | — |
| Cost of Revenue | — | $16.07B | $17.85B | $24.95B | $34.34B | $30.82B | $8.48B | $8.05B |
| Gross Profit | — | $46.51B | $45.78B | $33.54B | $65.99B | $50.47B | $33.42B | $32.85B |
| Gross Margin | — | 74.3% | 71.9% | 57.3% | 65.8% | 62.1% | 79.8% | 80.3% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | $13.79B | $14.73B | $14.77B | $13.68B | $12.70B | $11.60B | $12.73B |
| Operating Income | — | $10.19B | $11.11B | $3.27B | $35.97B | $25.60B | $8.49B | $12.89B |
| Operating Margin | — | 16.3% | 17.5% | 5.6% | 35.8% | 31.5% | 20.2% | 31.5% |
| Interest Expense | — | $2.67B | $3.09B | $2.21B | $1.24B | $1.29B | $1.45B | $1.57B |
| Pretax Income | — | $7.52B | $8.02B | $1.06B | $34.73B | $24.31B | $7.04B | $11.32B |
| Income Tax Expense | — | $-266.0M | $-28.0M | $-1.12B | $3.33B | $1.85B | $370.0M | $583.0M |
| Net Income | — | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B | $9.16B | $16.03B |
| Net Margin | — | 12.4% | 12.6% | 3.6% | 31.3% | 27.0% | 21.9% | 39.2% |
| EPS (Basic) | — | $1.37 | $1.42 | $0.38 | $5.59 | $3.92 | $1.65 | $2.88 |
| EPS (Diluted) | — | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 | $1.63 | $2.82 |
| Shares Outstanding (Basic) | 5.69B | 5.68B | 5.66B | 5.64B | 5.61B | 5.60B | 5.56B | 5.57B |
| Shares Outstanding (Diluted) | 5.69B | 5.71B | 5.70B | 5.71B | 5.73B | 5.71B | 5.63B | 5.68B |
| Dividends Per Share | — | $1.72 | $1.69 | $1.65 | $1.61 | $1.57 | $1.53 | $1.46 |